Sofosbuvir/ledipasvir safety and efficacy for HCV patients with haemodialysis and liver cirrhosis: a small retrospective study

Abstract Background Hepatitis C virus (HCV) infection is a high prevalent disease. Sofosbuvir/ledipasvir (SOF/LDV) can successfully treat HCV and it was until recently that SOF/LDV was approved by the FDA in haemodialysis patients, but not in patients with liver cirrhosis. This study reports patient...

全面介紹

書目詳細資料

Principais autores:	Ebtisam Boushi, Khaled Cheha, Noha Hedar, Rasha Almokdad, Mohammed Waleed Alassi, Ameer Kakaje
格式:	Artigo
語言:	Inglês
出版:	SpringerOpen 2021-10-01
叢編:	Egyptian Liver Journal
主題:	Cirrhosis End-stage kidney disease Haemodialysis Sofosbuvir/ledipasvir HCV
在線閱讀:	https://doi.org/10.1186/s43066-021-00150-3
標簽:	添加標簽 沒有標簽, 成為第一個標記此記錄!